Intravitreal Bevacizumab for Treatment of Refractory Central Serous Choroidoretinopathy
| Autor: | Morteza Entezari, Alireza Ramezani, Mehdi Yaseri |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Adult
Male medicine.medical_specialty Visual acuity genetic structures Bevacizumab Ophthalmic examination Visual Acuity Angiogenesis Inhibitors Case Report Central serous choroidoretinopathy Antibodies Monoclonal Humanized Refractory Ophthalmology medicine Humans Intravitreal bevacizumab Best corrected visual acuity Optical coherence tomography business.industry General Medicine Middle Aged eye diseases Surgery Serous fluid Treatment Outcome Central Serous Chorioretinopathy Intravitreal Injections Female sense organs medicine.symptom business Tomography Optical Coherence After treatment Follow-Up Studies medicine.drug |
| Zdroj: | Korean Journal of Ophthalmology : KJO |
| ISSN: | 2092-9382 1011-8942 |
| DOI: | 10.3341/kjo.2012.26.2.139 |
| Popis: | In a clinical case series, 5 patients with not-resolved central serous choroidoretinopathy (CSC) lasting more than 1 year received one intravitreal bevacizumab injection (IVB, 1.25 mg) injection. All patients underwent a through ophthalmic examination 1 day, 1 week, and 1, 2, and 6 months after the injection. Best corrected visual acuity (BCVA) and central macular thickness were compared before and after treatment by optical coherence tomography. Mean BCVA was improved significantly (p = 0.020) from 0.60 ± 0.25 to 0.50 ± 0.18 and 0.29 ± 0.19 logarithm of minimum angle of resolution at 6 and 18 weeks, respectively. Central macular thickness was also decreased significantly (p = 0.010) from 370 ± 65 to 208 ± 23 µm at 4 months. No recurrence was occurred during follow-up. IVB injection may have beneficial effect in the treatment of refractory CSC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|